These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31392864)

  • 1. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
    Twycross SH; Burger H; Holness J
    S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
    J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
    Schüle SC; Eigentler TK; Garbe C; la Fougère C; Nikolaou K; Pfannenberg C
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):482-8. PubMed ID: 26384681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
    Abbott RA; Acland KM; Harries M; O'Doherty M
    Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
    Kumar R; Alavi A
    Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorodeoxyglucose-PET in the management of malignant melanoma.
    Kumar R; Mavi A; Bural G; Alavi A
    Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
    Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
    Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
    Lee JW; Nam SB; Kim SJ
    Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
    Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
    J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
    Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
    J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
    Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
    Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
    Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
    J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of clinical impact of
    Liu J; Larcos G; Howle J; Veness M
    Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers.
    Annunziata S; Laudicella R; Caobelli F; Pizzuto DA; Aimn Working Group Y
    Curr Radiopharm; 2020; 13(1):6-13. PubMed ID: 31749438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
    Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET in early stage cutaneous malignant melanoma.
    McIvor J; Siew T; Campbell A; McCarthy M
    J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.